Have you seen the newest article from AF?
http://www.thestreet.com/_yahoo/story/10629106/1/biotech-stock-mailbag-fda-playbook.html?cm_ven=YAHOO&cm_cat=FREE&cm_ite=NA
Someone asked a question about DSCO and CERS and he went out of his way to say CVM is full of bull. Notice he didn't say a word abou their work with Johns Hopkins or their new facility. Its like he goes out of his way to drive the stock down. I really question this guy's motive.
VFC's Take: I agree, and as I've stated before, I believe that Feuerstein operates with motives other than simply reporting the news and commenting on it.
His blog posts have appeared with suspicious timing, in my opinion, and the fact that when he did go positive on a stock (BDSI), it was when a hedge fund was looking to exit the stock and surely benefited from the higher price that resulted from 'TheStreet.com' buy recommendation.
Coming from another angle, however, there's no doubt that Feuerstein's day job of blogging for the 'TheStreet.com' benefits anytime he mentions a popular stock because it draws viewers to his page. At the end of the day, he needs to attract readers to keep his job as top biotech blogger, so I think that stocks like DNDN, CVM and BIEL (among many others) will be mentioned as much as he can fit them into a blog post in an effort to draw as many viewers as he can.
After all, the man's gotta eat.
I noticed that I get a lot more viewership to my own blog when I post about a hot stock, that's what keyed me on to Feuerstein's game.
Another neat trick that he does to pump his 'clicks' statistics is making a one or two page blog post into an eight page ordeal. You read about a paragraph and a half of his article before having to click to the next page. All those clicks count as a click even when it's just one viewer clicking eight times to read one article, I'd presume.
Regarding the article (BIEL was also included in the most recent), I don't read his stuff anymore unless someone posts it on a message board. I've rarely felt that I got an un-biased view of a company or a stock from his blog postings and since I feel that 'TheStreet.com' has an agenda different than my own, I don't give them the clicks - especially not eight of them.
Manipulation can control the day to day price action of a stock, but overall, a good company and a good product combined with an investor's own DD will win out.
And as the reader who posted this comment mentioned - you can't have a conversation about CVM without including the ongoing Johns Hopkins study; any study being conducted in conjunction with JH gives instant credibility to that study.
More than likely, Feuerstein was trying to put a subtle CVM bash in that article, but he was also undoubtedly looking for a few clicks to his blog.
Disclosure: VFC is long CVM.


